Adagio Medical Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $2.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.30 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.31 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 2, 2025 | After market close | $137.00K | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $185.00K | – | – |
Press releases
Announcements Adagio Medical filed with the SEC
Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value
Exit or restructuring costs · Other events · EX-99 to Form 8-K
Adagio Medical Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Submits Premarket Approval Application
Other events · EX-99.1 to Form 8-K
Adagio Medical Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Announces Positive Pivotal Results
Other events · EX-99.1 to Form 8-K
Adagio Medical Receives IDE Approval from the
Other events · EX-99.1 to Form 8-K
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Closes Financing of $19 Million
Other events · EX-99.1 to Form 8-K
Adagio Medical Announces Pricing of up to Approximately
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Adagio Medical Unveils Preliminary Acute Results
Other events · EX-99.1 to Form 8-K
Ventricular Tachycardia: Interim Analysis of
Other events · EX-99.2 to Form 8-K
Adagio Medical, Inc. Announces Completion
Other events · EX-99.1 to Form 8-K
Adagio Medical Expands Chief Business Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Reports Second Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
of our Proprietary Ultra Low Temperature Cryoablation technology, the durability and reproducibility of the clinical data from our FULCRUM-VT pivotal study, our research, development and regulatory plans, and our strategy, future
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Adagio Medical Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Reports Fourth Quarter and Full
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Appoints Deborah Kaster as Chief Business Officer
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Adagio Medical Provides Clinical and Business
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Announces Strategic Restructuring
Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Adagio Medical Reports Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Adagio Medical Provides Business Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K